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Abstract
Background: The study aimed to explore the prevalence
of psychiatric disorders among orthotopic liver trans-
plantation (OLT) recipients, and to investigate how psy-
chiatric morbidity was linked to health-related quality of
life (HRQOL). Methods: We recruited 75 patients who
had undergone OLT a median of 3.8 years previously
(range = 5–129 months). Psychiatric morbidity was as-
sessed using the Structural Clinical Interview for the
DSM-III-R. Psychometric observer-rating and self-rating
scales were administered to evaluate cognitive function-
ing (SKT), depressive symptomatology (HAMD17), post-
traumatic stress symptoms (PTSS-10), social support
(SSS), and HRQOL (SF-36 Health Status Questionnaire).
Treatment characteristics were obtained from medical
records. Results: 22.7% (n = 17) of our sample had a cur-
rent or probable psychiatric diagnosis according to DSM-
III-R: 2.7% full posttraumatic stress disorder (PTSD) (n =
2), 2.7% major depressive disorder (MDD) comorbid to
full PTSD (n = 2), 1.3% MDD comorbid to partial PTSD
(n = 1), and 16% partial PTSD (n = 12). Patients with PTSD
symptoms demonstrated lower cognitive performance,
higher severity of depressive symptoms and more unfa-
vorable perception of social support. OLT-related PTSD
symptomatology was associated with maximal decre-
ments in HRQOL. The duration of intensive care treat-
ment, the number of medical complications, and the
occurrence of acute rejection were positively correlated
with the risk of PTSD symptoms subsequent to OLT.
Conclusion: OLT-related PTSD symptomatology impair-
ing HRQOL is a complication for a subgroup of OLT
recipients. Health-care providers should be aware of the
possible presence of PTSD in OLT survivors.
Copyright © 2002 S. Karger AG, Basel
Introduction
Owing to the introduction of more effective immuno-
suppressive agents such as cyclosporine (CsA) in 1980 and
tacrolimus (FK 506) in 1989, the standardization of the
surgical procedure, and the significant advances in inten-
sive care treatment, patient selection, tissue matching and
organ preservation, the clinical outcome of liver trans-
plant recipients has tremendously improved over the past
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15 years [1]. Orthotopic liver transplantation (OLT) is
now the treatment of choice for end-stage liver disease,
with 1-year survival rates in adult transplant recipients of
about 85% and 9-year survival rates of 55% in most of the
200 international centers including our Munich Liver
Transplantation Group with approximately 40 trans-
plants per annum [2, 3].
As transplantation surgery has dramatically advanced,
the success of OLT is no longer judged solely by its effects
on morbidity and mortality but by its influence on trans-
plant recipients’ psychosocial well-being [4]. In recent
years, a number of outcome studies have focused on
health-related quality of life (HRQOL) after liver trans-
plantation among adults, showing that OLT is associated
with improvement in HRQOL relative to the pretrans-
plant period, but without restoring the health status levels
described in the general population [5–7]. This finding
has raised concern about full psychosocial rehabilitation
in OLT. However, factors responsible for the persistent
difference remain poorly defined. Several studies empha-
sized the impact of recurrence of hepatitis C virus (HCV)
infection [8–11], CsA neurotoxicity [12–14], and mood
symptoms during corticosteroid therapy [15].
From a psychiatric point of view, clinical observations
point to psychiatric problems after OLT that may impair
HRQOL in liver transplant recipients [16, 17]. One study
has examined psychiatric complications of the postopera-
tive period of OLT in 63 adult liver transplant recipients.
The investigators found that psychiatric morbidity was
29%. Organic mental disorders were the most prevalent,
especially delirium (13%), followed by adjustment disor-
ders (8%), major depression (5%) and organic anxiety dis-
orders (3%) [18]. Surman et al. [19] reported that 20% of
40 adult liver transplant recipients were referred for treat-
ment of depressive disorder typically associated with
deterioration of hepatic status, infectious complication or
recurrence of cancer. To date, only two studies have
focused specifically on psychiatric morbidity and
HRQOL in adult intermediate-term survivors of OLT
[20, 21]. Commander et al. [20] found that psychiatric
morbidity in the 32 liver transplant recipients was associ-
ated with significant impairment in some areas of social
functioning. The prevalence rate of psychiatric morbidity
was 18.8% according to Research Diagnostic Criteria
[22], and major depressive disorder (MDD) accounted for
two thirds of all psychiatric diagnoses. Investigating 30
liver transplant recipients, Collis et al. [21] also demon-
strated that there was a significant association between
psychiatric morbidity and impaired HRQOL. They re-
corded a prevalence figure of 26.7%, using the Clinical
Interview Schedule [23]. Mild mixed anxiety and depres-
sive disorders accounted for 50%, severe depressive disor-
der for 12.5% of all psychiatric diagnoses.
The overall aim of the present outcome study was to
examine concurrently psychiatric morbidity including
cognitive deficits and psychopathologically relevant di-
mensions, and quality of life in intermediate-term survi-
vors of OLT, and to investigate how psychiatric morbidi-
ty is related to HRQOL. As previous research has docu-
mented that anxiety and depressive symptomatology are
most commonly present in a substantial portion of liver
transplant recipients, we were specifically interested in
the prevalence rate of posttraumatic stress disorder
(PTSD) in our patient population. In our view, it is con-
ceivable that OLT representing a ‘high-tech’ medical pro-
cedure associated with the risk of a variety of medical
complications (e.g. acute rejection, bleeding, infections)
during the intensive care unit (ICU) stay might be a trau-
matic stressor that is capable of producing posttraumatic
stress symptoms. We therefore examined variables such
as the extent of medical complications during the ICU
course subsequent to OLT, length of ICU stay, duration of
waiting period for OLT, type of liver failure, history of
retransplantation and of recurrence of HBV/HCV, and
preexisting trauma that may contribute in some way to
the development of posttraumatic stress symptoms in
OLT recipients. To our knowledge, this is the first study
that has addressed posttraumatic stress responses after
OLT in adult liver transplant recipients, and only one pre-
vious study has examined this issue in older children [24]
to date.
Subjects and Methods
Subjects and Procedure
Between March 1996 and October 1997, the outpatient clinic of
the Department of Medicine II at the Klinikum Grosshadern, the
tertiary care center of the Ludwig-Maximilians University, Munich,
Germany, treated 81 adult liver transplant recipients (age 16 or old-
er) who survived more than 5 months after undergoing OLT at our
transplantation center, who had CsA or tacrolimus (FK 506) concen-
trations in blood within therapeutic range, and who did not receive
steroid therapy. These 81 patients were approached by their physi-
cians from our outpatient clinic to participate. The refusal rate for
the present sample was 7.4% (n = 6). Respondents were indistin-
guishable from the few nonrespondents on transplant-related and
sociodemographic characteristics. Those agreeing were then con-
tacted by the research assistants, the study was explained, and
informed consent was obtained. Consenting patients were inter-
viewed by experienced consultation-liaison psychiatrists (H.-B.R.,
H.-P.K.), and completed the research battery at the time of a regular-
ly scheduled medical follow-up examination at the Klinikum Gross-
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hadern. The battery included a brief author-compiled questionnaire,
a structured clinical interview, self-report questionnaires, and psy-
chometric observer-rating scales. The study was approved by the
Institutional Review Board of our institution. Data protection met
the standard set by German law.
Sociodemographic and Clinical Characteristics
Information about patient and treatment characteristics were
obtained from a brief author-compiled questionnaire and from the
medical record. Demographic variables included age, gender, race,
marital status, and employment status at the time of the psychiatric
assessment. Marital status was categorized as married or living with a
spouse, single, divorced, or widowed. The patient’s employment sta-
tus was rated with respect to the following criteria: (a) full-time/part-
time employment, (b) unemployment, (c) retirement, (d) homemak-
ers in lieu of paid employment, and (e) disabled from work because of
health problems. According to WHO [25], disability is the conse-
quence of impairment, in terms of functional performance and activ-
ity by the afflicted person. Hence, we classified the OLT recipients as
disabled if they met criterion (e). Clinical characteristics included the
primary liver disease that led to end-stage liver disease and necessi-
tated OLT, as determined by the results of serologic, biochemical,
and histopathologic evaluations prior to the transplant surgery. His-
tory of medical complications during ICU treatment following OLT
was obtained from the medical record. They comprised acute rejec-
tion, gastrointestinal bleeding, acute renal failure, acute respiratory
distress syndrome, acute cardiovascular disturbances, delirium, vi-
ral, mycotic and/or bacterial infections. Further, the waiting period
for OLT, duration of ICU treatment following OLT, history of
retransplantation, history of recurrence of HBV or HCV positivity
after OLT, and the type of liver failure (acute vs. chronic) were
recorded. All medical information regarding treatment characteris-
tics and history of medical complications following OLT was col-
lected by experienced physicians from the outpatient clinic of the
Department of Medicine II (R.Z., M.B.).
Psychiatric Diagnosis
Two experienced psychiatrists from the consultation-liaison ser-
vice (H.-B.R., H.-P.K.) conducted the Structural Clinical Interview
for the DSM-III-R (SCID) [26, 27] to assess current and past psy-
chiatric diagnoses according to DSM-III-R criteria [28]. A sample of
15 randomly selected cases assessed by both raters [1 conducting the
interview (H.-B.R.) and 1 observing (H.-P.K.)] was used to assess
interrater reliability. The kappa for these 15 patients was 0.84, and
was considered to be adequate.
While psychiatric disorders other than PTSD were only assigned
to the OLT recipients when DSM-III-R criteria were completely met,
in the case of PTSD, we differentiated between a full PTSD and a
subthreshold or partial PTSD. According to our concept, OLT recipi-
ents received a subthreshold disorder of partial PTSD if they failed to
meet all the diagnostic criteria B (reexperiencing phenomena), C
(symptoms of avoidance and emotional numbing), D (symptoms of
increased arousal), but fulfilled two of these three key responses to
trauma and, additionally, the criteria A (trauma criterion), E (dura-
tion of the disturbance is more than 1 month), and F (the disturbance
causes clinically significant distress or psychosocial impairment).
The trauma criterion A was homogeneously defined as OLT. In order
to validly assess any pre-OLT relevant trauma or any post-OLT expo-
sure to traditional traumatic experiences other than our defined cri-
terion A stressor event for PTSD itself, we used the PTSD supple-
ment as included in the SCID. Since PTSD symptoms were rear-
ranged, but not changed, between DSM-III-R and DSM-IV [29], we
were able to generate DSM-IV diagnoses for PTSD.
Psychometric Tests
After completion of the SCID, pertinent psychometric observer-
rating and self-rating scales were administered to assess cognitive
functioning, depressive symptomatology, posttraumatic stress symp-
toms, social support, and HRQOL.
The neuropsychological evaluation was based on the SKT, a short
cognitive performance test including 9 subtests for assessing deficits
of memory and attention [30, 31]. Norm values range from 0 to 27,
and differentiate between profound (24–27), severe (19–23), moder-
ate (14–18), mild (9–13), questionable (5–8) cognitive impairments,
and no cognitive deficits (0–4). Published reliability data varied
between 0.86 and 0.88 [32]. The German version of the 17-item
Hamilton rating scale for depression (HAMD17) was used to measure
the severity of depressive symptomatology [33, 34]. According to
Paykel [35], a score of 18 points or more typically equals major
depression, and the range of 13–17 points is generally used to indi-
cate probable major depression. The Posttraumatic Stress Syndrome
10-Questions Inventory (PTSS-10) is a self-rating 10-item scale
based on the DSM-III [36] that measures the presence and intensity
of posttraumatic stress symptoms [37]. The German version of the
PTSS-10 (range: 10–70 points) has been successfully validated in
patients with PTSD after prolonged ICU treatment, and has proved
to be a reliable scale (Crohnbach’s alpha = 0.93). An optimal cut-off
score of 35 points of the questionnaire for diagnosis of PTSD has
been noted [38]. To evaluate the patients’ perception of a range of
socially supportive experiences, the Social Support Scale (SSS) [39]
was used. The German version of the SSS [40] is a self-report scale
with 19 items on a scale from 0 (never) to 4 (always), and a sum score
range from 0 to 76 points. Higher scores reflect a more favorable
perception of social support. To assess HRQOL after OLT in adult
liver transplant recipients, we applied the psychometrically validated
German translation of the Medical Outcome Study Short Form (SF-
36) [41, 42]. The SF-36 is a 36-item, self-rating questionnaire that
covers 8 health-related domains. Each domain yields a score ranging
from 0 to 100 (best). Published internal consistency data of the SF-36
exceeded 0.8 in the vast majority of the studies [43, 44].
Control Group for HRQOL Measurement
Control subjects were randomly selected from a large epidemio-
logical database (n = 3,000) used to provide standard values for the
SF-36 in a German population. Our HRQOL control group (n = 75)
represented age and gender-identical healthy subjects whose sociode-
mographic characteristics did not differ from the study sample.
Statistical Analyses
This outcome study examines the intermediate-term status in a
selected cohort of OLT recipients. The OLT recipients (n = 75) were
divided into three subcategories of patients based on whether the cri-
teria for PTSD according to DSM-III-R and DSM-IV were complete-
ly met, partially met, or not met at a median time of 3.8 years after
OLT. SF-36 data were compared with data from an age and gender-
matched control group of 75 healthy subjects. All statistical analyses
were performed using SPSS 10.0 for Windows (SPSS Inc., Chicago,
Ill., USA). Descriptive statistics were carried out on demographic,
treatment-related, and psychometric data (SF-36, PTSS-10, SKT,
HAMD17, SSS scores), and are presented as median B SD or mean
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Table 1. Sociodemographic characteristics of adult OLT recipients according to the diagnostic status of PTSD at the
time of psychiatric assessment
Category Total sample
(n = 75)
No PTSD
(n = 58)
Partial PTSD
(n = 13)
Full PTSD
(n = 4)
p
Gender
Male/female 43/32 33/25 6/7 4/0 0.1621
Age
Median, years
SD
Range, years
54
10.9
16–71
55
11.1
16–71
51
9.3
35–70
44.5
9.9
31–54
0.1982
Employment status
Disabled
Not disabled
27
48
19
39
6
7
2
2 0.5531
Marital status
Single
Married
Widowed
Divorced
11
59
2
3
8
47
1
2
2
10
1
–
1
2
–
1
0.2941
1 ¯2 tests.
2 Kruskal-Wallis one-way analysis of variance or ranks.
B SD, and ranges (minimum and maximum values, or 25th and 75th
percentiles) when appropriate. Kruskal-Wallis one-way analysis was
applied between the three subgroups of OLT recipients with full, par-
tial and no PTSD, and SKT, HAMD, PTSS-10, SF-36 scores, age,
time interval between OLT and psychiatric evaluation, ICU days,
waiting period for OLT, and number of medical complications dur-
ing ICU treatment. In this context, pairwise multiple comparison
procedures (Bonferroni) were used in order to determine which sub-
groups were significantly different. In the analysis of significant dis-
tribution differences for categorical variables between the three sub-
groups, we applied ¯ 2 tests. The nonparametric Wilcoxon signed rank
test was used for comparison of SF-36 data between the entire sample
of 75 OLT recipients and the age and gender-matched control group
of 75 healthy subjects. All tests were two-tailed. Significance was set
at p = 0.05 for all analyses.
Results
Clinical Status
A total of 44% (n = 33) of our entire sample (n = 75)
met the criteria for any lifetime diagnosis on the SCID:
alcohol abuse/dependence (n = 24; 32% of the sample),
other drug abuse/dependence (n = 3; 4% of the sample),
depressive disorders NOS (n = 3; 4% of the sample),
MDD (n = 2; 2.7% of the sample), and bipolar affective
disorder (n = 1; 1.3% of the sample). Prior psychiatric his-
tory did not reveal any lifetime diagnosis of PTSD in our
sample. 2.7% (n = 2) of our sample reported any lifetime
exposure to traditional stressors in terms of physical
attack.
22.7% (n = 17) of our entire sample (n = 75) had a
current or probable psychiatric diagnosis on the SCID:
full PTSD (n = 2; 2.7% of the sample), MDD comorbid to
partial PTSD (n = 1; 1.3% of the sample), and partial
PTSD (n = 12; 16.0% of the sample). Those participants
with lifetime histories of alcohol abuse/dependence or
other drug abuse/dependence were fully remitted at the
time of psychiatric assessment. Of the 13 current cases of
partial PTSD, 5 had histories of alcohol abuse/depen-
dence and 3 had histories of depressive disorders NOS. Of
the 4 current cases of full PTSD, 2 had histories of MDD.
None of the 2 patients reporting lifetime exposure to tra-
ditional stressors met the criteria for full or partial
PTSD.
Sociodemographic and Treatment Characteristics
Seventy-five out of 81 eligible OLT recipients were
enrolled in this psychiatric outcome study. All partici-
pants (32 females and 43 males) were Caucasian, and the
mean age was 52.2 years (SD = 10.9). The median time
interval between OLT and psychiatric assessment was 46
months (SD = 27.9; range 5–129 months). Table 1 sum-
marizes the sociodemographic characteristics, and table 2
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Table 2. Treatment characteristics of adult OLT recipients according to the diagnostic status of PTSD at the time of psychiatric assessment
Category Total sample
(n = 75)
No PTSD (I)
(n = 58)
Partial PTSD
(II) (n = 13)
Full PTSD (III)
(n = 4)
p I+III I+II II+III
Time interval
Median, months
SD
Range, months
46
27.9
5–129
45
28.6
5–129
63
27.0
25–120
42.5
13.9
32–65
0.2671
Waiting period
Median, days
SD
Range, days
22
38.1
1–205
28
41.0
1–205
11
21.1
1–76
8.5
4.1
1–10
0.0271 – – –
ICU days
Median, days
SD
Range, days
10
17.6
4–90
9
14.4
4–65
14
25.4
9–90
13
13.2
7–36
0.0111 – * –
Number of complications during ICU
Median
SD
Range
3
2.0
0–8
3
1.9
0–6
4
1.9
1–8
3
2.6
0–5
0.0391 – * –
Primary liver disease
Alcoholic liver disease
Infectious hepatitis2
PBC/PSC
Malignancy3
Miscellaneous4
24
17
9
5
20
19
13
8
4
14
5
1
1
1
5
0
3
0
0
1
0.3005
Type of liver failure
Acute liver failure
Chronic liver failure
13
62
9
49
4
9
0
4
0.2715
Complications during ICU treatment
Bleeding
Infections
Acute rejection
Cardiovascular
Acute renal failure
Delirium
ARDS
22
41
45
25
35
26
5
16
29
31
17
25
17
3
4
10
12
6
9
8
1
2
2
2
2
1
1
1
0.6305
0.2085
0.0325
0.3905
0.1565
0.0805
0.3035
History of retransplantation
Yes/No 9/66 5/53 4/9 0/4 0.0645
History of recurrence of HBV/HCV
Yes/No 16/59 12/46 2/9 2/2 0.3255
SD = Standard deviation; PBC = primary biliary cirrhosis; PSC = primary sclerosing cholangitis; ARDS = acute respiratory distress
syndrome. I, II, III: pair-wise multiple comparison procedures (Bonferroni). Statistically significant: * p ! 0.05.
1 Kruskal-Wallis one-way analysis of variance or ranks.
2 Infectious hepatitis encompasses HBV-related and/or HCV-related liver diseases.
3 Malignancy includes hepatocellular carcinoma and other hepatic malignancies.
4 Miscellaneous comprises Wilson’s disease, Budd-Chiari syndrome, fulminant hepatic failure, and cryptogenic cirrhosis.
5 ¯2 tests.
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Table 3. Test-psychological correlates of adult OLT recipients according to the diagnostic status of PTSD at the time of psychiatric assess-
ment
Category Total sample
(n = 75)
No PTSD (I)
(n = 58)
Partial PTSD (II)
(n = 13)
Full PTSD (III)
(n = 4)
p I+III I+II II+III
SKT 2.0
(0.0–14.0)
1.0
(0.0–8.0)
3.0
(1.0–14.0)
5.5
(4.0–8.0)
++ * * –
HAM-D17 4.0
(0.0–31.0)
2.0
(0.0–9.0)
7.0
(3.0–30.0)
22.0
(11.0–31.0)
+++ * * *
PTSS-10 18.0
(10.0–52.0)
16.0
(10.0–24.0)
29.0
(25.0–33.0)
47.0
(36.0–52.0)
+++ * * *
SSS 69.0
(14.0–76.0)
71.0
(14.0–76.0)
63.0
(28.0–76.0)
33.5
(14.0–62.0)
++ * – *
Values are median; scores in parentheses indicate minimum and maximum. +++ p ! 0.001; ++ p ! 0.01; + p ! 0.05 according to Kruskal-
Wallis one-way analysis of variance or ranks. I, II, III: pair-wise multiple comparison procedures (Bonferroni). Statistically significant:
* p ! 0.05.
presents information on the treatment characteristics of
the whole study sample and according to the diagnostic
status of PTSD at the time of psychiatric assessment (see
clinical status). The analysis of the employment status of
the entire sample showed that 21 of 75 OLT recipients
(28%) were full-time or part-time employed, 16 (21.3%)
were retired due to age-related reasons, 9 (12%) were
homemakers in lieu of paid employment, 2 (2.7%) were
unemployed, and 27 (36%) were disabled from work
because of health.
Results of Psychological Tests
Test-psychological correlates of our adult OLT recipi-
ents are depicted in table 3 for the entire sample and
according to the diagnostic status of PTSD at the time of
psychiatric assessment.
We found that the mean SKT total score (expressed as
norm values) from the whole sample of adult OLT recipi-
ents was 2.75 (SD = 2.75; median value = 2.0; range 0.0–
14.0) at a median time of 3.8 years after OLT, and lay well
under the cut-off point of 5. However, 17.3% (n = 13) of
the entire sample showed cognitive impairments as mea-
sured on the SKT (mean SKT total score = 7.54, SD =
2.88, range 5.0–14.0). No extreme and severe cognitive
deficits were recorded. A significant difference in cogni-
tive functioning between the subgroups was evident
(Kruskal-Wallis, H = 13.733, df = 2, p ! 0.01). Patients
without PTSD had significantly lower scores than those
with partial or full PTSD on the SKT. On the 17-item
HAMD, the entire sample of OLT recipients showed a
mean score of 5.33 (SD = 6.47; median value 4.0; range
0.0–31.0). Four patients scored 618, and 2 patients fell
within the range of 13–17 points on the HAMD17. How-
ever, only 3 out of these 6 patients fulfilled the diagnostic
criteria of MDD according to SCID. As illustrated on
table 3, a significant difference in the intensity of depres-
sive symptomatology between the three subgroups was
noted (Kruskal-Wallis, H = 26.938, df = 2, p ! 0.001):
patients with partial PTSD had significantly higher scores
than those without PTSD, and significantly lower scores
than those with full PTSD on the HAMD17. The results of
the PTSS-10 questionnaire in our sample discriminated
well with respect to the diagnostic status of PTSD accord-
ing to SCID (Kruskal-Wallis, H = 39.504, df = 2, p !
0.001). Adult OLT recipients with full PTSD scored an
average of 45.5 points (SD = 6.95; median value = 47.0;
range 36.0–52.0), and lay well above the cut-off score of
35. As shown in table 3, we recorded a significant differ-
ence in our subjects’ perception of supportive relation-
ships between the three subgroups (Kruskal-Wallis, H =
12.476, df = 2, p ! 0.01). Patients with full PTSD revealed
a marked tendency to perceive supportive relationships
less favorably than patients with partial PTSD and pa-
tients without PTSD on the SSS.
As shown in figure 1, our 75 participants performed
significantly worse on all health-related domains at a
median time of 3.8 years after OLT, when compared with
75 age and gender-matched healthy controls [Wilcoxon
signed rank test: physical functioning (PF), Z = –7.385,
p ! 0.001; role-physical (RP), Z = –5.420, p ! 0.001; bodi-
ly pain (BP), Z = –5.400, p ! 0.001; general health (GH),
Z = –6.160, p ! 0.001; vitality (V), Z = –5.131, p ! 0.001;
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Fig. 1. Mean scores B standard errors on
the SF-36 at the time of psychiatric assess-
ment data (n = 75 OLT recipients) compared
with 75 age- and gender-matched healthy
controls. Normal score = 100. *** p ! 0.001
(Wilcoxon signed rank test); ** p ! 0.01
(Wilcoxon signed rank test).
social functioning (SF), Z = –4.576, p ! 0.001; role-emo-
tional (RE), Z = –3.869, p ! 0.001; mental health (MH),
Z = –2.582, p ! 0.01].
Among the studied adult OLT recipients, patients with
full PTSD showed the lowest HRQOL, followed by pa-
tients with partial PTSD, and patients without PTSD
(fig. 2). Significant differences in PF (Kruskal-Wallis, H =
8.735, df = 2, p ! 0.05), RP (Kruskal-Wallis, H = 6.653,
df = 2, p ! 0.05), GH (Kruskal-Wallis, H = 6.709, df = 2,
p ! 0.05), V (Kruskal-Wallis, H = 16.774, df = 2, p !
0.001), RE (Kruskal-Wallis, H = 11.260, df = 2, p ! 0.01),
and MH (Kruskal-Wallis, H = 15.731, df = 2, p !
0.001) between the three subgroups were found. No signi-
ficant differences in BP (Kruskal-Wallis, H = 4.060, df =
2, p = 0.131) and SF (Kruskal-Wallis, H = 3.397, df = 2,
p = 0.183) between the three subgroups were evident.
Variables with a Possible Influence on the Risk of
PTSD
Variables that may have contributed in some way to
the development of posttraumatic stress symptoms in
OLT recipients are depicted in tables 1 and 2. The diag-
nostic status of full or partial PTSD in our cohort of adult
OLT recipients was not significantly related to any of the
following variables: gender (¯2 = 3.645, df = 2, p = 0.162),
age (Kruskal-Wallis, H = 3.244, df = 2, p = 0.198),
employment status (¯2 = 1.186, df = 2, p = 0.553), marital
status (¯2 = 7.295, df = 6, p = 0.294), number of months
from OLT to psychiatric-psychometric assessment (Krus-
kal-Wallis, H = 2.642, df = 2, p = 0.267), primary liver
disease (¯2 = 9.531, df = 8, p = 0.300), type of liver failure
(¯2 = 2.610, df = 2, p = 0.271), history of retransplantation
(¯2 = 5.510, df = 2, p = 0.064), history of recurrence of
HBV/HCV (¯2 = 2.247, df = 2, p = 0.325), medical com-
plications during ICU treatment following OLT in terms
of gastrointestinal bleeding (¯2 = 0.923, df = 2, p = 0.630),
viral, mycotic or bacterial infections (¯2 = 3.143, df = 2,
p = 0.208), acute cardiovascular disturbances (¯2 = 1.884,
df = 2, p = 0.390), acute renal failure (¯2 = 3.710, df = 2,
p = 0.156), delirium (¯2 = 5.044, df = 2, p = 0.080), and
acute respiratory stress syndrome (¯2 = 2.391, df = 2, p =
0.303). The duration of ICU treatment following OLT
(Kruskal-Wallis, H = 8.951, df = 2, p = 0.011), the total
number of medical complications during ICU treatment
(Kruskal-Wallis, H = 6.491, df = 2, p = 0.039), and the
occurrence of acute rejection during ICU treatment sub-
sequent to OLT (¯2 = 6.858, df = 2, p = 0.032), however,
were significantly positively correlated with the risk of
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Fig. 2. Comparison of the mean scores B
standard errors of the SF-36 HRQOL ques-
tionnaire between the three subgroups of
OLT recipients with no PTSD (n = 58), par-
tial PTSD (n = 13), and full PTSD (n = 4) at
the time of psychiatric assessment. Normal
score = 100. Significant differences between
groups were found on all domains but BP
and SF.
PTSD symptomatology following liver transplantation.
The length of the waiting period for OLT was negatively
correlated with the risk of partial and full PTSD (Kruskal-
Wallis, H = 7.233, df = 2, p = 0.027; patients with full
PTSD: median = 8.5 days; partial PTSD: median = 11
days; no PTSD: median = 28 days); however, Bonferroni
correction for pair-wise comparison showed no discrimi-
nation reaching statistical significance between the sub-
groups.
Discussion
Overall, the prevalence of psychiatric morbidity in this
sample of adult liver transplant recipients identified by
SCID according to DSM-III-R criteria was 22.7%. This
prevalence rate fell within the range for psychiatric mor-
bidity in adult intermediate-term survivors of OLT re-
ported in the two previous studies using Research Diag-
nostic Criteria (18.8%) [20] or Clinical Interview Sched-
ule (26.7%) [21]. It was comparable with the prevalence
rate of psychiatric morbidity in the general population, as
found in a German epidemiological study [45]. In accor-
dance with Commander et al. [20] and Collis et al. [21],
we found that anxiety disorders and depression were the
most frequent psychiatric diagnoses in OLT survivors.
17.3% of the OLT recipients displayed mild signs of
cognitive impairments at a median time of 3.8 years after
liver transplantation; however, none of these patients ful-
filled the criteria for any organic mental disorder accord-
ing to DSM-III-R. This was a main finding in terms of the
history of cognitive performance following OLT. As we
know from studies targeting organic mental disorders in
OLT candidates, the prevalence rate of delirium accord-
ing to DSM-III ranged from 16.7 to 18.6% [46, 47]. Ear-
lier reports of OLT recipients have even noted a 30–50%
prevalence of delirium or encephalopathy [19, 48, 49].
Following OLT, Vieta et al. [18] reported a 13% preva-
lence of delirium during the postoperative period until
discharge, and at a median time of 39 weeks after OLT,
Collis et al. [21] found a 3.3% prevalence of organic men-
tal disorder. OLT is obviously effective in reversing delir-
ious states owing to hepatic encephalopathy, and it has
been pointed out that improved neuropsychiatric func-
tion explained as much as 20% of improvement in quality
of life in OLT recipients [50]. However, it has also been
stated that cognitive functioning is restored to a large
extent, but not completely, subsequent to OLT [51]. This
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observation concurs with our results. As we found a posi-
tive correlation between severity of PTSD symptoms and
cognitive disturbances, it is conceivable that our observed
cognitive impairments may be related to psychological
distress in terms of PTSD symptoms. At least, Bremner’s
study [52] has demonstrated that PTSD may be associat-
ed with cognitive dysfunction.
The most interesting result of our study resides in the
observation that a significant minority of the studied
adult OLT survivors developed posttraumatic stress
symptoms as a consequence of OLT. We found that 5.3%
of the patients met DSM-III-R criteria for a current diag-
nosis of full PTSD, and 17.3% of the patients for a partial
PTSD at a median time of 3.8 years after OLT. Despite
the increasing consideration of medically related post-
traumatic stress symptoms in a large body of literature
over the past 5 years, only three previous studies system-
atically addressed the issues of posttraumatic stress symp-
toms related to solid organ transplantation [24, 53, 54].
Walker et al. [24] interviewed 18 children aged between 7
and 16 years at a mean time of 16.94 months after liver
transplantation by using the Child Posttraumatic Stress
Reaction Index (CPTS-RI). The concordance between the
CPTS-RI ratings and the DSM-III-R criteria for a diagno-
sis of PTSD has been found to be high [55]. The study
demonstrated that 11% of the studied patients fell within
the severe range of posttraumatic stress, 11% fell within
the moderate range, and 56% fell within the mild range.
These results indicated that the acute life threat involved
in the liver transplantation contributed to the develop-
ment of posttraumatic stress. Using the PTSD module of
the Composite International Diagnostic Interview (CIDI)
[56] that yields a diagnosis of the disorder based on DSM-
III-R criteria, Stukas et al. [53] found that 10.8% of the
158 studied heart transplant recipients met the full crite-
ria for a diagnosis of PTSD, and an additional 5% of the
patients were probable cases at 12 months after transplan-
tation. Most recently, Grandi et al. [54] investigated 129
heart transplant recipients who had undergone transplan-
tation 1 month previously. Using the Italian version of the
SCID for the DSM-IV, they recorded a 26.3% figure of
anxiety disorders in their sample. Full PTSD (7%) and
generalized anxiety disorder (7%) constituted the most
frequent diagnostic categories in their heart transplant
recipients.
There are at least four possible explanations for the
observed difference in full and partial PTSD prevalence
rates across the studies. First, OLT recipients in the cur-
rent study were interviewed at a median time of 46
months after OLT, whereas in the other studies, psychiat-
ric assessments were conducted at 1, 16.94 or 12 months
after solid organ transplantation. A recent epidemiologi-
cal study has demonstrated that approximately 26% of
PTSD cases remitted by 6 months, and 40% by 12
months, and even from that point on, remission contin-
ued, although it tapered off [57]. Reflecting this clinical
course of PTSD, we could speculate that a portion of our
studied patients suffering from a partial PTSD at the time
the evaluation was conducted might have experienced a
partial remission from a full PTSD over time. On the oth-
er hand, we have to state that our retrospective analysis of
lifetime diagnoses by using SCID-I did not reveal a histo-
ry of full PTSD in those patients meeting the criteria for a
current partial PTSD. Second, we investigated adult OLT
recipients with a mean age of 52.2 years, whereas Walker
et al. [24] studied children with a mean age of 11.8 years.
Published studies suggest that younger age represents an
important risk factor for PTSD [58, 59]. Third, different
types of physical traumata and medical illnesses may pro-
duce different rates of full PTSD and partial PTSD. For
example, Kapfhammer et al. [60] found that 23.9% of the
investigated 46 long-term survivors of the acute respirato-
ry distress syndrome suffered from a full PTSD, and
17.8% from a partial PTSD, as detected by a full diagnos-
tic assessment with the Structured Clinical Interview for
DSM-IV, while Green et al. [61] described that only 2.5%
of the studied 160 women with an early-stage breast can-
cer met stringent criteria for cancer-related PTSD accord-
ing to DSM-III-R. Madianos et al. [62] examining 45
patients with burn injuries reported a 20% prevalence of
PTSD according to DSM-III-R criteria. Fourth, our stud-
ied sample only included OLT recipients who had CsA or
FK 506 concentrations in blood within therapeutic range.
Hence, our participants represented a selected cohort of
OLT recipients who were highly compliant with medica-
tions. One study has recently demonstrated that post-
transplant medical compliance and mental health pre-
dicted physical morbidity and mortality 1–3 years after
heart transplantation, and that the risk of cardiac allograft
disease was elevated by anxiety and depressive symptom-
atology [63]. Considering these results, one could specu-
late that those OLT recipients showing CsA or FK 506
blood levels not within the target range were noncom-
pliant with immunosuppressive therapy owing to psycho-
logical factors such as depressive and anxiety disorders
including PTSD. Mayou and Smith [64] emphasized that
a partial or full syndrome of PTSD could be associated
with avoidance of medical care and poor compliance with
treatment. One study investigating the prevalence of non-
compliance with immunosuppressive medication in 118
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OLT recipients documented a figure of 16% at a mean
follow-up time of 53.7 months [65]. Given that OLT
recipients with immunosuppressive concentrations in
blood not within the target range were enrolled in our
study, it is possible that the prevalence of full PTSD in
OLT recipients may be similar to that observed in the
study by Stukas et al. [53].
It is particularly noteworthy that 50% of our patients
meeting DSM-III-R criteria for full PTSD were comorbid
with major depression, while only 7.7% of those patients
suffering from partial PTSD occurred with major depres-
sion. From a point of view of depression, it is worth con-
sidering that an additional 15.4% of the patients with par-
tial PTSD scored 13 points or more on the HAMD17, indi-
cating major depression. However, the HAMD17 scale
was not designed to be used for diagnostic purposes and is
only used for measuring the severity of symptoms once a
diagnosis has been made. Therefore, our comorbidity
data only partly concur with the observations made by
Kessler et al. [66] in a recent epidemiologic survey. Con-
sidering the fact that 50% of our patients with full PTSD
had lifetime histories of MDD, and only 23% of our
patients with partial PTSD had lifetime histories of de-
pressive disorders NOS, we could raise the hypothesis
that patients with a personal psychiatric history of mood
disorders might be more susceptible to the development
of OLT-related PTSD than those without previous affec-
tive disorders. At least, our analysis of possible risk vari-
ables for PTSD symptomatology revealed that the length
of ICU stay and number of complications during ICU did
not significantly differ in our studied OLT recipients with
full PTSD from those without PTSD, whereas patients
with partial PTSD had been treated significantly longer in
the ICU and had experienced significantly more compli-
cations during ICU than those without PTSD. We agree
with Jacobsen et al. [67] that a longer treatment duration
in the ICU is due to the increased incidence of medical
complications that may be perceived as life-threatening
associated with feelings of fear, helplessness or horror,
and therefore may increase the potential for the develop-
ment of PTSD symptomatology. Other variables that may
contribute in some way to the development of PTSD
symptoms such as gender, age, waiting period for OLT,
primary liver disease, type of liver failure, history of
retransplantation, and history of recurrence of HBV/
HCV were not significantly different between the studied
patients with full, partial, or no PTSD. Regarding the
recurrence of HBV/HCV, it is worth discussing that this
information is certainly associated with psychological dis-
tress for the patients as a rapid progression of the infec-
tion cannot be ruled out; however, this stressor is a
future-oriented one, since in most cases, prognosis is good
and progression of liver disease is relatively slow. The
nature of this stressor, therefore, may not fit the PTSD
model well. Most interestingly, the occurrence of acute
rejection during ICU treatment was a significant predic-
tor of PTSD symptomatology. In fact, experiencing epi-
sodes of acute rejections played a major role for the OLT
recipients’ subjective perception of trauma. According to
contemporary immunosuppressive strategies [68], pa-
tients with acute rejection were initially treated with pulse
intravenous methylprednisolone, up to 1 g/day for 3 con-
secutive days. As we know from literature [69, 70], tran-
sient disruption of sleep, altered perception, and lability
of mood often occurs among those receiving ‘supraphar-
macologic’ doses of glucocorticoids as an antirejection
therapy. Besides, from a psychobiological perspective,
one could speculate that ‘pulses’ of glucocorticoids might
have an influence on the development of PTSD symp-
tomatology. Theoretically, glucocorticoid excess could
have neurotoxic effects, particularly in the hippocampus,
a primary neural glucocorticoid target site, and it has been
hypothesized that hippocampal damage appears to be a
correlate of PTSD itself, as decreased hippocampal func-
tioning may cause behavioral disinhibition by promoting
the definition of incoming stimuli in the direction of fight/
flight responses [71, 72]. However, the role of glucocorti-
coid pulse therapy in the development of PTSD seems to
be very speculative because the role of glucocorticoids in
PTSD is controversial, and, generally, the instances of
glucocorticoid-induced hippocampal atrophy require pro-
longed or repeated bursts of glucocorticoid excess [73].
A major aim of the present study was to explore the
relation between psychiatric morbidity in OLT recipients
and HRQOL. HRQOL in the entire sample of our
patients was characterized by statistically significant de-
crements in all eight domains of the SF-36 when com-
pared with a German age and gender-matched healthy
control group. This finding was only partly in accordance
with the results reported by Bravata et al. [7] who quanti-
tatively synthesized the complete published English-lan-
guage literature on HRQOL after liver transplantation.
They reported that the SF-36 scores from the studied 468
OLT recipients were not significantly different from those
of the general US population, except in the pain domain.
Besides, we found 64% employed at the time the evalua-
tion was performed. This figure was quite similar to the
average overall employment rates in other recent studies
[74]. In accordance with the other two previous studies
investigating the relation between psychiatric morbidity
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and HRQOL [20, 21], our study demonstrates that there
was a significant association between psychiatric morbid-
ity and impaired HRQOL. In detail, OLT recipients ful-
filling DSM-III-R criteria for PTSD, either comorbid with
MDD or not, manifested the most impaired mental and
physical health status and perceived supportive relation-
ships most unfavorably, followed by those with subthresh-
old expressions of PTSD, whereas OLT recipients without
current or probable psychiatric disorders showed the most
favorable health status. The finding regarding mental
health subscales suggests that PTSD symptomatology
subsequent to OLT is a clinically relevant phenomenon.
So far as the physical health subscales are concerned, one
could argue that either the presence of PTSD symptom-
atology had adverse health effects that made them less
able to cope with activities in daily living, or that their
physical health was worse and reminded them of traumat-
ic aspects of their ICU treatment following OLT.
Finally, there are several limitations of this study to be
respected. First, the varying time intervals between OLT
and psychiatric evaluation. Second, the study was retro-
spective in design. A recall bias might have significantly
lowered the report on any psychiatric disorder and trau-
matic experiences prior to and following OLT. Third, no
pretransplant measures of psychiatric symptomatology
and other psychosocial variables including SF-36 baseline
data were available with which to compare our findings.
Fourth, the sample was a selected cohort of OLT recipi-
ents. Although our decision to consider OLT recipients
only eligible for enrollment if they had CsA or FK 506
concentrations in blood within therapeutic range certain-
ly helped to avoid confounding present cognitive deficits,
mood and anxiety phenomena with cyclosporine-associ-
ated or tacrolimus-associated organic mental distur-
bances; it is possible that the prevalence rate of PTSD
symptomatology would have been higher if we had in-
cluded patients who were not compliant with immuno-
suppressive medication. Fifth, the conduction of brain
magnetic resonance imaging examining the hippocam-
pus, psychophysiologic and endocrinological evaluations
should be proposed in future studies in order to measure
presumed neurobiological correlates of PTSD itself that
could add objectivity to the assessment of PTSD. Sixth,
the inclusion of appropriate control groups (e.g. heart
transplant recipients) needs to be considered in forthcom-
ing studies, and future research should also include longi-
tudinal study designs. Seventh, the Diagnostic Criteria for
Psychosomatic Research, as proposed by Fava et al. [75],
should be used in future studies in order to improve the
identification of psychological factors which could result
in a worsening of HRQOL in OLT recipients [54, 76–
78].
In conclusion, our study demonstrated that a subgroup
of intermediate-term survivors of OLT exhibited PTSD
symptomatology that was related to impaired HRQOL.
This finding highlights the need to be aware of the possi-
ble presence of PTSD in OLT survivors who present to
health-care providers with a variety of common psychiat-
ric symptoms such as sleep difficulties and poor concen-
tration. HRQOL may be improved in affected OLT recip-
ients by attenuating posttraumatic stress symptoms. De-
finitive psychotherapeutical and pharmacotherapeutical
treatment approaches for PTSD exist.
Acknowledgments
The authors wish to thank Prof. Dr. Monika Bullinger and Mat-
thias Morfeld, MA, from the Institute of Medical Psychology, Uni-
versity Hospital Eppendorf, Hamburg, Germany, for providing con-
trol group data of the SF-36 health survey.
References
1 Wood RP, Ozaki CF, Katz SM, Monsour HP
Jr, Dyer CH, Johnston TD: Liver transplanta-
tion. The last ten years. Surg Clin of North Am
1994;74:1133–1154.
2 Seaberg EC, Belle SH, Beringer KC, Schivins
JL, Detre KM: Long-term patient and retrans-
plantation-free survival by selected recipient
and donor characteristics: An update from the
Pitt-UNOS liver transplant registry; in Cecka
JM, Terasaki PI (eds): Clinical Transplants
1997. Los Angeles, UCLA Tissue Typing Labo-
ratory, 1998, vol 13, pp 15–28.
3 Rust C, Rau H, Gerbes AL, Pape GR, Haller
M, Kramling H, Schildberg FW, Paumgartner
G, Beuers U: Liver transplantation in primary
biliary cirrhosis: Risk assessment and 11-year
follow-up. Digestion 2000;62:38–43.
4 Freeman AM 3rd, Westphal JR, Davis LL,
Libb JW: The future of organ transplant psy-
chiatry. Psychosomatics 1995;36:429–437.
5 Dew MA, Switzer GE, Goycoolea JM, Allen
AS, DiMartini A, Kormos RL, Griffith BP:
Does transplantation produce quality of life
benefits? Transplantation 1997;64:1261–
1273.
6 Tarter RE: Quality of life following liver trans-
plantation. Hepatogastroenterology 1998;45:
1398–1403.
7 Bravata DM, Olkin I, Barnato AE, Keeffe EB,
Owens DK: Health-related quality of life after
liver transplantation: A meta-analysis. Liver
Transpl Surg 1999;5:318–331.
8 Dickson RC, Wright RM, Bacchetta MD,
Bodily SE, Caldwell SH, Driscoll CJ, Pruett
TL, Ishitani MB: Quality of life of hepatitis B
and C patients after liver transplantation. Clin
Transplant 1997;11:282–285.
296 Psychother Psychosom 2002;71:285–297 Rothenhäusler/Ehrentraut/Kapfhammer/
Lang/Zachoval/Bilzer/Schelling/Gerbes
9 Singh N, Gayowski T, Wagener MM, Marino
IR: Quality of life, functional status, and de-
pression in male liver transplant recipients
with recurrent viral hepatitis C. Transplanta-
tion 1999;67:69–72.
10 De Bona M, Ponton P, Ermani M, Iemmolo
RM, Feltrin A, Boccagni P, Gerunda G, Nacca-
rato R, Rupolo G, Burra P: The impact of liver
disease and medical complications on quality
of life and psychological distress before and
after liver transplantation. J Hepatol 2000;33:
609–615.
11 Paterson DL, Gayowski T, Wannstedt CF, Wa-
gener MM, Marino IR, Vargas H, Laskus T,
Rakela J, Singh N: Quality of life in long-term
survivors after liver transplantation: Impact of
recurrent viral hepatitis C virus hepatitis. Clin
Transplant 2000;14:48–54.
12 Craven JL: Cyclosporine-associated organic
mental disorders in liver transplant recipients.
Psychosomatics 1991;32:94–102.
13 DiMartini A, et al: Neuropsychiatric side ef-
fects of FK 506 vs. cyclosporin A. First-week
postoperative findings. Psychosomatics 1997;
38:565–569.
14 Gijtenbeek JMM, van den Bent MJ, Vecht CJ:
Cyclosporine neurotoxicity: A review. J Neurol
1999;246:339–346.
15 Brown ES, Suppers T: Mood symptoms during
corticosteroid therapy: A review. Harv Rev
Psychiatry 1998;5:239–246.
16 Greiner CB, Roccaforte W: Psychiatric issues
in liver transplantation. Semin Liver Dis 1989;
9:184–188.
17 Surman OS: Psychiatric aspects of liver trans-
plantation. Psychosomatics 1994;35:297–307.
18 Vieta E, de Pablo J, Cirera E, Pujol A, Grande
L, Rimola A, Visa J: Postoperative psychiatric
complications following liver transplantation.
Med Clin (Barc) 1993;100:210–213.
19 Surman OS, Dienstag JL, Cosimi AB, Chaun-
cey S, Russell PS: Psychosomatic aspects of liv-
er transplantation. Psychother Psychosom
1987;48:26–31.
20 Commander M, Neuberger J, Dean C: Psy-
chiatric and social consequences of liver trans-
plantation. Transplantation 1992;53:1038–
1040.
21 Collis I, Burroughs A, Rolles K, Lloyd G: Psy-
chiatric and social outcome of liver transplan-
tation. Br J Psychiatry 1995;166:521–524.
22 Spitzer RL, Endicott J, Robins E: Research
diagnostic criteria: Rationale and reliability.
Arch Gen Psychiatry 1978;35:773–782.
23 Goldberg D, Cooper B, Eastwood MR, Ked-
ward HB, Shepherd M: A standardized psy-
chiatric interview for use in community sur-
veys. Br J Prev Soc Med 1970;24:18–23.
24 Walker AM, Harris G, Baker A, Kelly D,
Houghton J: Post-traumatic stress responses
following liver transplantation in older chil-
dren. J Child Psychol Psychiatry 1999;40:363–
374.
25 World Health Organization: International
Classification of Impairments, Disabilities,
and Handicaps. A Manual of Classification Re-
lating to the Consequences of Disease. Geneva,
World Health Organization, 1982.
26 Spitzer RL, Williams JBW, Gibbon M, First
MB: Structured Clinical Interview for DSM-
III-R, Patient Edition (SCID-P, Version 1.0).
Washington, American Psychiatric Press,
1990.
27 Wittchen HU, Zaudig M, Schramm E, Speng-
ler P, Mombour W, Klug J, Horn R: Struktu-
riertes klinisches Interview für DSM-III-R
(SKID). Weinheim, Beltz Test Gesellschaft,
1991.
28 American Psychiatric Association: Diagnostic
and Statistical Manual of Mental Disorders, ed
3, revised. Washington, American Psychiatric
Press, 1987.
29 American Psychiatric Association: Diagnostic
and Statistical Manual of Mental Disorders, ed
4. Washington, American Psychiatric Press,
1994.
30 Erzigkeit H: SKT – Ein Kurztest zur Erfassung
von Gedächtnis- und Aufmerksamkeitsstö-
rungen. Weinheim, Beltz, 1989.
31 Overall JE, Schaltenbrand R: The SKT neuro-
psychological test battery. J Geriatr Psychiatry
Neurol 1992;5:220–227.
32 Lehfeld H, Erzigkeit H: The SKT: A short cog-
nitive performance test for assessing deficits of
memory and attention. Int Psychogeriatr 1997;
9(suppl 1):115–121.
33 Hamilton M: Development of a rating scale for
primary depressive illness. Br J Soc Clin Psy-
chol 1967;6:278–296.
34 Möller HJ: Methodological aspects in the as-
sessment of severity of depression by the Ham-
ilton Depression Scale. Eur Arch Psychiatry
Clin Neurosci 2001;251(suppl 2):13–20.
35 Paykel ES: Use of the Hamilton Depression
Scale in general practice. Psychopharmacol Ser
1990;9:40–47.
36 American Psychiatric Association: Diagnostic
and Statistical Manual of Mental Disorders, ed
3. Washington, American Psychiatric Press,
1980.
37 Weisaeth L: Torture of a Norwegian ship’s
crew. The torture, stress reactions and psy-
chiatric after-effects. Acta Psychiatr Scand
Suppl 1989;355:63–72.
38 Stoll C, Kapfhammer HP, Rothenhäusler HB,
Haller M, Briegel J, Schmidt M, Krauseneck T,
Durst K, Schelling G: Sensitivity and specifici-
ty of a screening test to document traumatic
experiences and to diagnose post-traumatic
stress disorder in patients after intensive care
treatment. Intensive Care Med 1999;25:697–
704.
39 Donald CA, Ware JE: The measurement of
social support. Res Commun Ment Health
1984;4:325–370.
40 Kirchberger J, Bullinger M: Der Social Support
Fragebogen. Göttingen, Hogrefe, 2001.
41 Stewart A, Hays R, Ware JE Jr: The MOS
short-form general health survey. Reliability
and validity in a patient population. Med Care
1988;26:724–732.
42 Bullinger M, Kirchberger I: Der SF-36 Frage-
bogen zum Gesundheitszustand. Göttingen,
Hogreve, 1998.
43 Ware JE Jr, Sherbourne C: The MOS 36-item
short-form healthy survey. 1. Conceptual
framework and item selection. Med Care 1992;
30:473–483.
44 Schelling G, Stoll C, Haller M, Briegel J, Ma-
nert W, Hummel T, Lenhart A, Heyduck M,
Polasek J, Meier M, Preuss U, Bullinger M,
Schüffel W, Peter K: Health-related quality of
life and post-traumatic stress disorder in survi-
vors of the acute respiratory distress syndrome.
Crit Care Med 1998;26:651–659.
45 Fichter MM, Narrow WE, Roper MT, Rehm J,
Elton M, Rae DS, Locke BZ, Regier DA: Preva-
lence of mental illness in Germany and the
United States. Comparison of the Upper Ba-
varian Study and the Epidemiologic Catch-
ment Area Program. J Nerv Ment Dis 1996;
184:598–606.
46 Trzepacz PT, Brenner RP, Coffman G, Van
Thiel DH: Delirium in liver transplantation
candidates: Discrimination analysis of multi-
ple test variables. Biol Psychiatry 1988;24:3–
14.
47 Trzepacz PT, Brenner RP, Van Thiel DH: A
psychiatric study of 247 liver transplantation
candidates. Psychosomatics 1989;30:147–153.
48 House R, Dubovsky SL, Penn I: Psychiatric
aspects of hepatic transplantation. Transplan-
tation 1983;36:146–150.
49 Trzepacz PT, Maue FR, Coffman G, Van Thiel
DH: Neuropsychiatric assessment of liver
transplantation candidates: Delirium and other
psychiatric disorders. Int J Psychiatry Med
1986;16:101–111.
50 Tarter RE, Switala J, Plail J, Havrilla J, Van
Thiel DH: Severity of hepatic encephalopathy
before liver transplantation is associated with
quality of life after transplantation. Arch Intern
Med 1992;152:2097–2101.
51 Tarter RE, Switala JA, Arria A, Plail J, Van
Thiel DH: Subclinical hepatic encephalopathy.
Comparison before and after orthotopic liver
transplantation. Transplantation 1990;50:
632–637.
52 Bremner JD: Alterations in brain structure and
function associated with post-traumatic stress
disorder. Semin Clin Neuropsychiatry 1999;4:
249–255.
53 Stukas AA, Dew MA, Switzer GE, DiMartini
A, Kormos RL, Griffith BP: PTSD in heart
transplant recipients and their primary family
caregivers. Psychosomatics 1999;40:212–221.
54 Grandi S, Fabbri S, Tossani E, Mangelli L,
Branzi A, Magelli C: Psychological evaluation
after cardiac transplantation: The integration
of different criteria. Psychother Psychosom
2001;70:176–183.
55 Pynoos RS, Goenjian A, Tashjian M, Karaka-
shian M, Manjikian R, Manoukian G, Stein-
berg AM, Fairbanks LA: Post-traumatic stress
reactions in children after the 1988 Armenian
earthquake. Br J Psychiatry 1993;163:239–
247.
56 World Health Organization: Composite Inter-
national Diagnostic Interview (CIDI), Version
1.0. Geneva, World Health Organization,
1990.
Psychiatric and Psychosocial Outcome of
OLT
Psychother Psychosom 2002;71:285–297 297
57 Breslau N, Kessler RC, Chilcoat HD, Schultz
LR, Davis GC, Andreski P: Trauma and post-
traumatic stress disorder in the community:
The 1996 Detroit Area Survey of Trauma.
Arch Gen Psychiatry 1998;55:626–632.
58 Green BL, Grace MC, Lindy JD, Gleser GC,
Leonhard A: Risk factors for PTSD and other
diagnoses in a general sample of Vietnam vet-
erans. Am J Psychiatry 1990;147:729–733.
59 Norris FH: Epidemiology of trauma: Frequen-
cy and impact of different potentially traumat-
ic events on different demographic groups. J
Consult Clin Psychol 1992;60:409–418.
60 Kapfhammer HP, Rothenhäusler HB, Krau-
seneck T, Stoll C, Schelling G: Posttraumatic
stress disorder and health-related quality of life
in long-term survivors of acute respiratory dis-
tress syndrome. Am J Psychiatry 2002; in
press.
61 Green BL, Rowland JH, Krupnick JL, Epstein
SA, Stockton P, Stern NM, Spertus IL, Steakley
C: Prevalence of posttraumatic stress disorder
in women with breast cancer. Psychosomatics
1998;39:102–111.
62 Madianos MG, Papaghelis M, Ionnovich J,
Dafni R: Psychiatric disorders in burn patients:
A follow-up study. Psychother Psychosom
2001;70:30–37.
63 Dew MA, Kormos RL, Roth LH, Murali S,
DiMartini A, Griffith BP: Early post-trans-
plant medical compliance and mental health
predict physical morbidity and mortality one
to three years after heart transplantation. J
Heart Lung Transplant 1999;18:549–562.
64 Mayou R, Smith KA: Post-traumatic symp-
toms following medical illness and treatment. J
Psychosom Res 1997;43:121–123.
65 Berlakovich GA, Langer F, Freundorfer E,
Windhager T, Rockenschaub S, Sporn E, Soli-
man T, Pokorny H, Steininger R, Mühlbacher
F: General compliance after liver transplanta-
tion for alcoholic cirrhosis. Transpl Int 2000;
13:129–135.
66 Kessler R, Sonnega A, Bromet E, Highes M,
Nelson CB: Posttraumatic stress disorder in the
National Comorbidity Survey. Arch Gen Psy-
chiatry 1995;52:1048–1060.
67 Jacobsen PB, Widows MR, Hann DM, Andry-
kowski MA, Kronish LE, Fields KK: Posttrau-
matic stress disorder symptoms after bone
marrow transplantation for breast cancer. Psy-
chosom Med 1998;60:366–371.
68 Elias E: Liver transplantation. J R Coll of Phy-
sicians Lond 1993;27:224–232.
69 Surman OS: Psychiatric aspects of organ trans-
plantation. Am J Psychiatry 1989;146:972–
982.
70 Kershner P, Wang-Cheng R: Psychiatric side
effects of steroid therapy. Psychosomatics
1989;30:135–139.
71 Squire LR, Zola-Morgan S: The medial tempo-
ral lobe memory system. Science 1991;253:
2380–2386.
72 Van der Kolk BA: The psychobiology of post-
traumatic stress disorder. J Clin Psychiatry
1997;58(suppl 9):16–24.
73 Sapolsky RM: Glucocorticoids and hippocam-
pal atrophy in neuropsychiatric disorders. Arch
Gen Psychiatry 2000;57:925–935.
74 Bravata DM, Olkin I, Barnato AE, Keeffe EB,
Owens DK: Employment and alcohol use after
liver transplantation for alcoholic and nonalco-
holic liver disease: A systematic review. Liver
Transpl 2001;7:191–203.
75 Fava GA, Freyberger H, Bech P, Christodou-
lou G, Sensky T, Theorell T, Wise TN: Diag-
nostic criteria for use in psychosomatic re-
search. Psychother Psychosom 1995;63:1–8.
76 Fava GA, Mangelli L, Ruini C: Assessment of
psychological distress in the setting of medical
disease. Psychother Psychosom 2001;70:171–
175.
77 Porcelli P, De Carne M, Fava GA: Assessing
somatization in functional gastrointestinal dis-
orders. Psychother Psychosom 2000;69:198–
204.
78 Porcelli P, De Carne M: Criterion-related val-
idity of the diagnostic criteria for psychosomat-
ic research for alexithymia in patients with
functional gastrointestinal disorders. Psycho-
ther Psychosom 2001;70:184–188.
